Jane de Vries
Publications and Insights
- Publication: A global landscape analysis of access to tumour-agnostic therapies
- Publication: Capturing the lived experiences of informal care in acute leukemia
- Publication: The commercial case for investing in ALS
- Publication: Patient preferences for treatment in relapsed/refractory acute leukemia
- Publication: The broader economic benefits of COVID-19 vaccination
- Publication: Altering the trajectory of HIV in Europe
- Publication: Understanding societal preferences for priority by disease severity in England & Wales
- Publication: Inequalities in Dementia: Unveiling the Evidence and Forging a Path Towards Greater Understanding
- Publication: How Have HTA Agencies Evolved Their Methods Over Time?
- Publication: Socio-Economic Value of Adult Immunisation Programmes
- Insight: Navigating the Intersection of Healthcare and Environmental Sustainability: ISPOR Europe round-up on the inclusion of environmental impact in HTA
- Insight: Around The World in HTAs: The Slovak Republic – Valuing the Future
- Publication: Are Recommendations for HTA of Gene Therapies Being Achieved?
- Publication: Dementia in the UK: Estimating the Potential Future Impact and Return on Research Investment
- Insight: Setting the Right Discount Rate for HTA in the Slovak Republic
- Publication: Real-World Evidence: Current Best Practice for Reimbursement Decision-Making
- Publication: Delivering the Triple Win: A Value-Based Approach to Pricing
- Insight: Caring about Carers: Improving Consideration of the Burden of Informal Caring in HTA
- Insight: Cost-effectiveness Analysis of Gene Therapies for Inherited Eye Disease: Are Current Discounting Approaches Too Short-sighted?
- Publication: The Case for Expanding Uptake of Next-Generation Sequencing for Lung Cancer in Europe
- Publication: Navigating the Landscape of Digital Health – United Kingdom
- New: OHE is Leading Research to Develop an EQ-5D ‘Bolt-on’ for Hearing
- Insight: Estimating the Impact of U.S. Drug Price-setting Policies on Innovation Is Challenging, Even for the Congressional Budget Office
- Publication: Supporting the Era of Green Pharmaceuticals in the UK
- Publication: Health Technology Assessment of Gene Therapies: Are Our Methods Fit for Purpose?
- Publication: Limitations of CBO’s Simulation Model of New Drug Development as a Tool for Policymakers